With no approved drugs for congenital muscular dystrophy, patients often die in their teens. MD Pharma AB is developing autophagy inhibitors that could extend and improve quality of life for a subgroup of patients.

The subtypes of congenital muscular dystrophy (MD) are defined by the genetic mutations and defective proteins that lead to muscle loss.